関連する実験動画
Updated: Jul 17, 2025

08:09
Mapping the Binding Site of an Aptamer on ATP Using MicroScale Thermophoresis
Published on: January 7, 2017
10.7K
クセノアプタマーと標的タンパク質における,水害性の非自然な塩基の厳密な相互作用
Michiko Kimoto1, Hui Pen Tan1, Ken-Ichiro Matsunaga1
1Xenolis Pte. Ltd., 85 Science Park Drive, #02-05B, The Cavendish, Singapore 118259, Singapore.
Journal of the American Chemical Society
|September 7, 2023
まとめ
研究者は,非自然基 (UB) を改変することによって,XenoAptamersを最適化しました. 新しい変種であるYsとBsは,標的タンパク質に対するXenoAptamer結合親和性を著しく強化し,特定の分子内相互作用を明らかにした.
科学分野:
- 生物化学と分子生物学
- 合成生物学
- バイオテクノロジー
背景:
- XenoAptamersは,タンパク質の結合を強化するための非自然な塩基 (UBs) を含むDNAアプタマーである.
- 水嫌性UB7-(2-チエニル) イミダゾ[4,5-b]ピリジン (Ds) は,XenoAptamerの親和性を増加させるが,その最適な構造は不明である.
- Dsは当初,PCRベースのアプタマー生成と補完的なUB,Pxのために開発された.
研究 の 目的:
- XenoAptamersの第5文字 (水害性UB) のリガンド構造を最適化するために.
- XenoAptamerの親和性に対するDsの構造変化の影響を調査する.
- 標的タンパク質へのXenoAptamer結合を改善する新しいUB変種を特定する.
主な方法:
- Dsの非自然な塩基の13の変種を合成した.
- これらのDs変種を含むXenoAptamersの生成.
- 結合試験を用いた修正されたXenoAptamersの親和性評価
主要な成果:
- Dsの微妙な構造の変化は,XenoAptamerの親和性を有意に変化させた.
- 4- ((2-チエニル)) ピロロ[2,3-b]ピリジン (Ys) または4- (((2-チエニル)) ベンジミダゾール (Bs) を含んだXenoAptamersは,標的タンパク質の親和性を大幅に改善した.
- 一つの窒素が炭素原子に置き換えられた Ds 変種です.
結論:
- UBsと標的タンパク質との結合相互作用は,単に水害性の接触ではなく,特定の分子内相互作用です.
- UBの構造的最適化は,XenoAptamerの親和性を成熟させるための実行可能な戦略である.
- YsとBsは,高親和性のXenoAptamersを開発するための有望な非自然な基礎を表しています.
関連する概念動画
DNA Base Pairing
27.5K
Erwin Chargaff’s rules on DNA equivalence paved the way for the discovery of base pairing in DNA. Chargaff’s rules state that in a double-stranded DNA molecule,
27.5K
Ligand Binding Sites
12.9K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
12.9K
Transfer RNA Synthesis
12.0K
One of the unique features of tRNA is the presence of modified bases. In some tRNAs, modified bases account for nearly 20% of the total bases in the molecule. Altogether, these unusual bases protect the tRNA from enzymatic degradation by RNases.
Each of these chemical modifications is carried by a specific enzyme, post-transcription. All of these enzymes have unique base and site-specificity. Methylation, the most common chemical modification, is carried by at least nine different enzymes, with...
Each of these chemical modifications is carried by a specific enzyme, post-transcription. All of these enzymes have unique base and site-specificity. Methylation, the most common chemical modification, is carried by at least nine different enzymes, with...
12.0K
Drug-Receptor Bonds
2.9K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
2.9K
Targets for Drug Action: Overview
6.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.4K

